Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR AMPLIFICATION ( ENST00000275493.7 )
EGFR AMPLIFICATION ( ENST00000275493.7 )
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/854
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/190
Rating
3
Evidence Type
Predictive
Disease
Colorectal Cancer
Evidence Direction
Supports
Drug
Panitumumab,Cetuximab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
24653627
Drugs
Drug NameSensitivitySupported
CetuximabSensitivitytrue
PanitumumabSensitivitytrue